(Q28584214)

31 January 2017

title

Targeting the erythropoietin receptor on glioma cells reduces tumour growth (English)

1 reference

Emmanuèle Lechapt-Zalcman

31 January 2017

1 reference

7

Emmanuèle Lechapt-Zalcman

0 references

Elodie A Pérès

Elodie A. Pérès

1

0 references

Samuel Valable

Samuel Valable

2

0 references

Myriam Bernaudin

Myriam Bernaudin

8

0 references

author name string

Jean-Sébastien Guillamo

3

1 reference

31 January 2017

Léna Marteau

4

1 reference

31 January 2017

Jean-François Bernaudin

5

1 reference

31 January 2017

Simon Roussel

6

1 reference

31 January 2017

Edwige Petit

9

1 reference

31 January 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

Experimental Cell Research

31 January 2017

published in

1 reference

31 January 2017

volume

317

1 reference

31 January 2017

issue

16

1 reference

31 January 2017

page(s)

2321–2332

1 reference

Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus

31 January 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin receptor mRNA expression in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin and normal brain development: receptor expression determines multi-tissue response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin after a century of research: younger than ever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin biology in cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Expression of erythropoietin receptor splice variants in human cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin receptors on tumor cells: what do they mean?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin regulates tumour growth of human malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Absence of functional EpoR expression in human tumor cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Survival and invasiveness of astrocytomas promoted by erythropoietin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Prognostic significance of tumor oxygenation in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Expression of erythropoietin and its receptor in neuroblastomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin augments survival of glioma cells after radiation and temozolomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

The regulated expression of erythropoietin by two human hepatoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

HIF1 and oxygen sensing in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Pediatric Tumor Cells Express Erythropoietin and a Functional Erythropoietin Receptor that Promotes Angiogenesis and Tumor Cell Survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

Functional significance of erythropoietin receptor expression in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.06.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEXCR.2011.06.011

1 reference

31 January 2017

1 reference